Skip to main content
Caplight Logo









Tilikum Therapeutics

Tilikum Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://tilikumtx.com/

Last Round

Seed

Jun 1, 2023

Company Overview

Tilikum Therapeutics is a biotechnology company developing a new class of small-molecule PARP1-selective inhibitors to treat treatment-resistant solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

PARP inhibitoroncologybiotechnologydrug discoverysolid tumorsPARP-lockingsmall-molecule inhibitorprecision medicinecancer therapeuticsclinical-stage biotechbiopharmadrug pipelineDNA-repairtherapeutic assets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tilikum Therapeutics Comparables

Compare Tilikum Therapeutics with similar companies based on industry and business-model similarity.

Tilikum Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Acerand Therapeutics
87%
Eikon Therapeutics
76%
IMPACT Therapeutics
73%

Tilikum Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 1, 2023

Tilikum Therapeutics Investors

Notable investors and investment history

Tilikum Therapeutics investors
InvestorRounds
Delin VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2023

    Seed round led by Delin Ventures.

Tilikum Therapeutics Filings

Explore SEC and related filing metadata, where available.

Tilikum Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Tilikum Therapeutics's valuation, stock price, and market status.

Is Tilikum Therapeutics a public or private company?

Tilikum Therapeutics is a private company.

What is the current stock price of Tilikum Therapeutics?

Tilikum Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Tilikum Therapeutics worth (valuation)?

Valuation information for Tilikum Therapeutics is not publicly available.

Can I buy Tilikum Therapeutics stock?

Tilikum Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Tilikum Therapeutics's last funding round?

Tilikum Therapeutics's most recent funding round was Seed on June 1, 2023.

Who are the main investors in Tilikum Therapeutics?

Key investors in Tilikum Therapeutics include Delin Ventures.

Will Tilikum Therapeutics IPO soon?

No public IPO plans have been announced for Tilikum Therapeutics.

How can I track Tilikum Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tilikum Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Year Founded2022
Last FundingJun 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?